-transparent.png){kind=logo}
Coronary thrombosis leading to myocardial infarction is a complex process involving the interaction of the arterial wall, the coagulation cascade, and platelets. Increased understanding of the molecular biology of thrombosis has prompted an evolution in antithrombotic therapy, from the early use of warfarin following myocardial infarction to agents targeting specific receptors or modulators in the thrombotic process. The complexity of thrombosis allows for numerous sites of pharmacologic intervention; the multiple pathways leading to platelet aggregation and thrombin formation provide the opportunity for combined therapies. This review presents the current clinical data on antiplatelet, anticoagulant, and specific antithrombin therapies following myocardial infarction.
G T Almony, and
J Lefkovits, and
E J Topol
January 1991,
Henry Ford Hospital medical journal,
G T Almony, and
J Lefkovits, and
E J Topol
March 1980,
The Medical letter on drugs and therapeutics,
G T Almony, and
J Lefkovits, and
E J Topol
May 1969,
British medical journal,
G T Almony, and
J Lefkovits, and
E J Topol
January 1984,
La Ricerca in clinica e in laboratorio,
G T Almony, and
J Lefkovits, and
E J Topol
February 1990,
The American journal of cardiology,
G T Almony, and
J Lefkovits, and
E J Topol
September 1960,
Canadian Medical Association journal,
G T Almony, and
J Lefkovits, and
E J Topol
September 1962,
Lancet (London, England),
G T Almony, and
J Lefkovits, and
E J Topol
October 1959,
Canadian Medical Association journal,
G T Almony, and
J Lefkovits, and
E J Topol
May 1970,
British medical journal,
G T Almony, and
J Lefkovits, and
E J Topol
July 1969,
The New England journal of medicine,
